Der Wert von Worten:Michael Serrer aus dem Literaturbüro Düsseldorf im Interview mit der Textpraxis-Redaktion

Die Textpraxis-Redaktion unterhält sich mit Michael Serrer über Literaturvermittlung in Zeiten der Digitalisierung, über Kanonisierung und die Rolle der Literatur in der Gesellschaft. Michael Serrer ist Leiter des Literaturbüros NRW und Feuilletonist

3-D modelling and assessment of tidal current resources in the Bay of Fundy, Canada

The Bay of Fundy, located between the Canadian Provinces of Nova Scotia and New Brunswick, is home to the world’s largest tides and has long been identified as one of the world’s premier resources of tidal energy. This paper describes the development of a high resolution three-dimensional hydrodynamic model of tidal flows in the Bay of Fundy, and its application to help quantify and assess the kinetic energy resource throughout the Bay. Information on the scale and character of the tidal currents and the associated kinetic energy resource is presented herein for three of the most energetic parts of the Bay: near Long Island, Passamaquoddy Bay and Minas Passage (where a $70 million pre-commercial deployment of in-stream turbines is presently underway)

PSED 2000

NRC publication: Ye

An Integrated production planning and scheduling system for manufacturing plants

Peer reviewed: YesNRC publication: Ye

An Integrated production planning and scheduling system for manufacturing plants

Peer reviewed: YesNRC publication: Ye

A Production planning and scheduling system for manufacturing plants

Peer reviewed: YesNRC publication: Ye

The clinically used iron chelator deferasirox is an inhibitor of epigenetic jumonjiC domain-containing histone demethylases

Fe(II)- and 2-oxoglutarate (2OG)-dependent JumonjiC domain-containing histone demethylases (JmjC KDMs) are epigenetic eraser enzymes involved in the regulation of gene expression and are emerging drug targets in oncology. We screened a set of clinically used iron chelators and report that they potently inhibit JMJD2A (KDM4A) in vitro. Mode of action investigations revealed that one compound, deferasirox, is a bona fide active site-binding inhibitor as shown by kinetic and spectroscopic studies. Synthesis of derivatives with improved cell permeability resulted in significant upregulation of histone trimethylation and potent cancer cell growth inhibition. Deferasirox was also found to similarly inhibit human 2OG-dependent hypoxia inducible factor prolyl hydroxylase activity. Therapeutic effects of clinically used deferasirox may thus involve transcriptional regulation through 2OG oxygenase inhibition. Deferasirox might provide a useful starting point for the development of novel anticancer drugs targeting 2OG oxygenases and a valuable tool compound for investigations of KDM function

The Clinically Used Iron Chelator Deferasirox Is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases

Fe(II)- and 2-oxoglutarate (2OG)-dependent JumonjiC domain-containing histone demethylases (JmjC KDMs) are epigenetic eraser enzymes involved in the regulation of gene expression and are emerging drug targets in oncology. We screened a set of clinically used iron chelators and report that they potently inhibit JMJD2A (KDM4A) in vitro. Mode of action investigations revealed that one compound, deferasirox, is a bona fide active site-binding inhibitor as shown by kinetic and spectroscopic studies. Synthesis of derivatives with improved cell permeability resulted in significant upregulation of histone trimethylation and potent cancer cell growth inhibition. Deferasirox was also found to similarly inhibit human 2OG-dependent hypoxia inducible factor prolyl hydroxylase activity. Therapeutic effects of clinically used deferasirox may thus involve transcriptional regulation through 2OG oxygenase inhibition. Deferasirox may provide a useful starting point for the development of novel anticancer drugs targeting 2OG oxygenases and a valuable tool compound for investigations of KDM function.<br /